Supplementary Figure S20 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Q: What type of study is this?

This is a Phase 2 study (also classified as: RCT).

Chang Gon Kim; Min Hee Hong; Dahee Kim; Brian Hyohyoung Lee; Hyunwook Kim; Chan‐Young Ock; Geoffrey Kelly; Yoon Ji Bang; Gamin Kim; Jung Eun Lee; Chaeyeon Kim; Se‐Heon Kim; Hyun Jun Hong; Young Min Park; Nam Suk Sim; Heejung Park; Jin Woo Park; Chang Geol Lee; Kyung Hwan Kim; Goeun Park; Inkyung Jung; Dawoon Han; Jong Hoon Kim; Junha Cha; Insuk Lee; Mingu Kang; Heon Song; Chiyoon Oum; Seulki Kim; Sukjun Kim; Yoojoo Lim; Seunghee Kim‐Schulze; Miriam Mérad; Sun Och Yoon; Hyun Je Kim; Yoon Woo Koh; Hye Ryun Kim

doi:10.1158/1078-0432.29996673

Key Points

Neoadjuvant treatment with durvalumab plus tremelimumab showed immune flares in head and neck cancer patients.
Immune responses were observed particularly after treatment with different combinations of therapies.
The research involved a phase II randomized clinical trial assessing these therapeutic effects.
Observations on immune flare responses highlight variability that may inform future cancer treatment strategies.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Open-label randomized trial assesses immune response in head and neck cancer patients receiving durvalumab or tremelimumab, indicating unique reactions post-treatment.

Abstract

Case studies of nodal immune flares after neoadjuvant durvalumab (A) and durvalumab+tremelimumab (B) therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2025) studied this question.

synapsesocial.com/papers/68bb3a352b87ece8dc954cc4 https://doi.org/10.1158/1078-0432.29996673

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S20 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S20 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading